Glucotrack's subsidiary, Lokahi Therapeutics, announced its first external fee-for-service partnership with nonprofit Innovate GBM. This deal, leveraging Lokahi's AI platform for identifying brain tumor therapeutic assets, caused GCTK shares to surge over 80% in after-hours trading, indicating a significant positive market reaction to this new revenue stream and validation of its technology.
Glucotrack's subsidiary, Lokahi Therapeutics, secured its first external fee-for-service partnership with Innovate GBM, a nonprofit focused on glioblastoma research. This is significant because it marks the first commercial validation of Lokahi's proprietary AI-driven asset identification platform, ai² PIPELINE, and represents a new revenue stream for the company. The market reacted strongly, with GCTK shares jumping over 80% after hours, indicating that investors view this as a positive catalyst. While the immediate financial impact might be small given the company's low market cap and prior performance, it offers a potential long-term opportunity for Glucotrack to scale its technology beyond its core medical device business. Traders should note the high volatility and the stock's historical decline, but this partnership could signal a turning point for the company's diversification strategy.